This site is intended for healthcare professionals
Login | Register (NOW FREE)

Medical search


FREE subscriptions for doctors and students... click here
You have 3 open access pages.

Ethosuximide is used mainly in the treatment of petit mal epilepsy. However, it is also useful in akinetic and myoclonic attacks associated with generalised EEG spike-and-wave paroxysms.

Occasionally it is necessary to use a combination of sodium valproate and ethosuximide to control complex absences. This combination may also be used in patients with combined absence and tonic-clonic seizures where valproate may fail to satisfactorily control the absences.

The peak serum levels of ethosuximide occur 1-4 hours after administration and the control of absence seizures is highly correlated with plasma levels.

The summary of product characteristics should be consulted before prescribing this drug.


The information provided herein should not be used for diagnosis or treatment of any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2016 Oxbridge Solutions LtdĀ®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions LtdĀ® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.